Recordati Strengthens Rare Diseases Portfolio with Acquisition of Global Rights to Enjaymo
Recordati announces an agreement with Sanofi to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold…
Read More...
Read More...
